Morgan Stanley’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,774,307
| Closed | -$3.62M | – | 8446 |
|
|
2021
Q3 | $3.62M | Sell |
1,774,307
-183,044
| -9% | -$426K | ﹤0.01% | 4055 |
|
|
2021
Q2 | $5.81M | Sell |
1,957,351
-372,529
| -16% | -$984K | ﹤0.01% | 3628 |
|
|
2021
Q1 | $6.43M | Buy |
2,329,880
+376,782
| +19% | +$1.14M | ﹤0.01% | 3141 |
|
|
2020
Q4 | $4.75M | Buy |
1,953,098
+54,130
| +3% | +$130K | ﹤0.01% | 3313 |
|
|
2020
Q3 | $3.99M | Buy |
1,898,968
+548,737
| +41% | +$1.85M | ﹤0.01% | 2937 |
|
|
2020
Q2 | $5.1M | Buy |
1,350,231
+1,115,248
| +475% | +$3.34M | ﹤0.01% | 2643 |
|
|
2020
Q1 | $444K | Buy |
234,983
+185,394
| +374% | +$482K | ﹤0.01% | 4442 |
|
|
2019
Q4 | $104K | Buy |
49,589
+37,145
| +298% | +$71.2K | ﹤0.01% | 5642 |
|
|
2019
Q3 | $29K | Buy |
12,444
+10,261
| +470% | +$27.6K | ﹤0.01% | 5909 |
|
|
2019
Q2 | $7K | Sell |
2,183
-69,081
| -97% | -$254K | ﹤0.01% | 6251 |
|
|
2019
Q1 | $355K | Buy |
71,264
+59,920
| +528% | +$295K | ﹤0.01% | 4757 |
|
|
2018
Q4 | $50K | Sell |
11,344
-27,194
| -71% | -$133K | ﹤0.01% | 5765 |
|
|
2018
Q3 | $187K | Sell |
38,538
-155,583
| -80% | -$796K | ﹤0.01% | 5486 |
|
|
2018
Q2 | $1.16M | Buy |
194,121
+83,568
| +76% | +$611K | ﹤0.01% | 4519 |
|
|
2018
Q1 | $973K | Buy |
110,553
+38,836
| +54% | +$291K | ﹤0.01% | 4559 |
|
|
2017
Q4 | $520K | Buy |
71,717
+43,448
| +154% | +$271K | ﹤0.01% | 4962 |
|
|
2017
Q3 | $195K | Buy |
28,269
+8,026
| +40% | +$55.4K | ﹤0.01% | 5368 |
|
|
2017
Q2 | $145K | Buy |
20,243
+15,643
| +340% | +$72.3K | ﹤0.01% | 5487 |
|
|
2017
Q1 | $22K | Buy |
+4,600
| New | +$14.1K | ﹤0.01% | 6065 |
|
Morgan Stanley's SBBP Position: Q4 2021 in Review
Morgan Stanley sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 1,774,307 shares — an estimated $3.62M sold.
Morgan Stanley first reported a position in SBBP in Q1 2017 and held it in 19 quarters. The position peaked at $6.43M in Q1 2021. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Morgan Stanley reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Morgan Stanley sold 1,774,307 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $3.62M.
- Morgan Stanley first reported a position in Strongbridge Biopharma plc. in Q1 2017 and held it in 19 quarters.
- Morgan Stanley's Strongbridge Biopharma plc. position peaked at $6.43M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.